Evaluation Study on the Accuracy of PET-CT in Clinical Staging of Lymphoma

Yue Jing （ General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750000, China ）

Abstract

Objective: To evaluate the accuracy of PET-CT in the clinical staging of lymphoma and to provide reliable evidence for the formulation of clinical treatment plans and prognosis assessment. Methods: The clinical data of 86 patients with pathologically confirmed lymphoma who received diagnosis and treatment in our hospital from March 2022 to March 2024 were retrospectively analyzed. The accuracy, sensitivity, and specificity of PET-CT were compared with those of conventional imaging in lymphoma clinical staging, and the detection of occult lesions by PET-CT was recorded. Results: A total of 86 patients were included, including 23 cases of Hodgkin lymphoma and 63 cases of non-Hodgkin lymphoma. Based on the Ann Arbor staging system, 18 cases were stage I, 25 cases stage II, 29 cases stage III, and 14 cases stage IV. The overall staging accuracy of PET-CT was 91.86% (79/86), significantly higher than that of traditional imaging (76.74%, 66/86). The corresponding diagnostic accuracy for each stage was 88.89% in stage I, 92.00% in stage II, 93.10% in stage III, and 89.29% in stage IV. Its sensitivity and specificity both exceeded 85%. In addition, PET-CT successfully identified 12 occult lesions that were not detected by conventional imaging, including 4 cases of bone marrow infiltration, 5 cases of distant lymph node metastasis, and 3 cases of extranodal involvement. Conclusion: PET-CT can accurately reflect the metabolic activity and extent of tumor dissemination, and it demonstrates superior performance over traditional imaging techniques in improving the accuracy of lymphoma clinical staging.

Keywords

Full Text

References